This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Eid, M. A. Articles by Kumar, M. V. Search for Related Content PubMed PubMed Citation Articles by Eid, M. A. Articles by Kumar, M. V.

Medical College of Georgia, Section of Urology, and the Veterans Administration Medical Center, Augusta, Georgia 30912

Examination of the effects of TRAIL (tumor necrosis factor -related apoptosis-inducing ligand) showed higher apoptotic response in LNCaP C4-2, whereas LNCaP were resistant. However, treatment of LNCaP with Mifepristone, an antiprogestin, before TRAIL induced significant apoptosis, similar to the levels observed in LNCaP C4-2. Experiments to determine the reasons for altered response of the cell lines showed no significant differences in death/decoy receptors and caspase-8 activity. However, treatment induced increased truncation of Bid and activation of caspases -9, -7, and -3 in LNCaP C4-2. Time course experiments showed that caspase-8 was activated before the involvement of mitochondrial pathway, and caspase-9 was responsible for activation of caspases -7 and -3. Use of specific caspase inhibitors demonstrated the presence of a short-loop feedback activation of Bid. Published reports suggested that increased phosphorylation of Akt was responsible for resistance of LNCaP to TRAIL. However, no significant differences were noticed in the levels of phosphorylated Akt in TRAIL-resistant LNCaP and TRAIL-sensitive LNCaP C4-2. On the basis of our results, it is suggested that the differences in response of the two cell lines to TRAIL is at the mitochondrial level.

This article has been cited by other articles:

				I. Kaddour-Djebbar, V. Lakshmikanthan, R. B. Shirley, Y. Ma, R. W. Lewis, and M. V. Kumar Therapeutic advantage of combining calcium channel blockers and TRAIL in prostate cancer. Mol. Cancer Ther., August 1, 2006; 5(8): 1958 - 1966. [Abstract] [Full Text] [PDF]

				Q. Xu, S. Takekida, N. Ohara, W. Chen, R. Sitruk-Ware, E. D. B. Johansson, and T. Maruo Progesterone Receptor Modulator CDB-2914 Down-Regulates Proliferative Cell Nuclear Antigen and Bcl-2 Protein Expression and Up-Regulates Caspase-3 and Poly(Adenosine 5'-Diphosphate-ribose) Polymerase Expression in Cultured Human Uterine Leiomyoma Cells J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 953 - 961. [Abstract] [Full Text] [PDF]

				M. EL-Gohary and M. A Eid Effect of cannabinoid ingestion (in the form of bhang) on the immune system of high school and university students Human and Experimental Toxicology, March 1, 2004; 23(3): 149 - 156. [Abstract] [PDF]

				L.-N. Song, M. Coghlan, and E. P. Gelmann Antiandrogen Effects of Mifepristone on Coactivator and Corepressor Interactions with the Androgen Receptor Mol. Endocrinol., January 1, 2004; 18(1): 70 - 85. [Abstract] [Full Text] [PDF]